Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase
These findings reveal that imatinib mesylate effectively reduces the carcinogenic function of c-MYC in DHL, providing novel strategies for developing therapies targeting c-MYC-driven DHL.
Authors
- Yan Tu (ORCID: https://orcid.org/0000-0002-0443-7037)
- Sisi Jiang (ORCID: https://orcid.org/0000-0002-7430-9639)
- Sheng Zhou (ORCID: https://orcid.org/0000-0003-3578-7926)
- Huixian Hu
- Fang He (ORCID: https://orcid.org/0000-0002-9106-1938)
- JingCheng Zhang
Institutions
- Jinhua Academy of Agricultural Sciences (CN)
- Jinhua Central Hospital (CN)
- Anyang Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1007/s00432-024-05939-4
- Citations
- 1
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.44
Funders
- Zhejiang Medical Association